Patent application number | Description | Published |
20080227170 | Use of Pit Emulsions in Biocatalytic Reactions - Oil-in-water emulsions produced by the phase inversion temperature process, with droplet sizes of 50 to 400 nm, for use as the reaction medium for biocatalytic reactions. | 09-18-2008 |
20100234458 | Process for the Production of Fatty Acid Alkyl Esters - Disclosed is an improved process for the production of fatty acid lower alkyl esters according to formula (I) | 09-16-2010 |
20100323415 | Emulsions in Enzymatic Reactions - A reaction medium for enzyme-catalyzed reactions is provided, comprising an oil-in-water emulsion including water, an emulsifier, an oil phase and at least one interfacially active enzyme, where the emulsion is produced by the phase inversion temperature process and has a droplet size of 50 to 400 nm. A method for the enzyme-catalyzed esterification, transesterification or hydrolysis of fatty acid alkyl esters and/or triglycerides is also provided where the oil-in-water emulsion is used as the reaction medium. | 12-23-2010 |
20120065419 | METHOD FOR PRODUCING RICINOLEIC ACID ESTER BY SELECTIVE ENZYMATIC TRANSESTERIFICATION - The present invention relates to a method for preparing ricinoleic acid ester from a pure or mixed vegetable oil, in particular castor oil, wherein the method includes at least the step of enzymatic transesterification in the presence of a light alcohol and using a typo-selective lipase in order to obtain a fraction enriched with ricinoleic acid ester. The method according to the invention for producing ricinoleic acid ester includes the steps: i) a first transesterification reaction in the presence of a light alcohol and a lipase extracted from | 03-15-2012 |
Patent application number | Description | Published |
20090221805 | Complex polymere amphiphile-PDGF - Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups. | 09-03-2009 |
20100081708 | ANTICOAGULANT COMPOUNDS - The present invention is concerned with anticoagulants (i.e. substances that stop blood from clotting). More specifically, the present invention is concerned with orally available antithrombic oligosaccharides. | 04-01-2010 |
20110301086 | Complex polymere amphiphile-PDGF - Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups. | 12-08-2011 |
20120316132 | PHARMACEUTICAL ORAL DOSAGE FORM CONTAINING A SYNTHETIC OLIGOSACCHARIDE - The present invention concerns a pharmaceutical formulation intended for oral administration containing a synthetic oligosaccharides containing one to 18 monosaccharide units and having a therapeutical activity or a pharmaceutically acceptable additions salt or solvate thereof wherein the formulation contains: a) the synthetic oligosaccharide (A) in an amount of up to 5% by weight of the total weight of the formulation, advantageously up to 1% by weight of the total weight of the formulation, b), a lipophilic phase (B) consisting of triglyceride of fatty acids in an amount of 50 to 80% by weight of the total weight of the formulation, advantageously of 50 to 70% by weight of the total weight of the formulation, c) at least one lipophilic surfactant (C) with HLB below 7 consisting of partial esters of polyol and fatty acids in an amount of 10 to 30% by weight of the total weight of the formulation, advantageously of 15 to 30% by weight of the total weight of the formulation, d) at least one hydrophilic surfactant (D) with HLB above 7 in an amount of up to 20% by weight of the total weight of the formulation, advantageously up to 15% by weight of the total weight of the formulation, e) optionally, at least one hydrophilic solvent (E) in an amount of up to 15% by weight of the total weight of the formulation, advantageously up to 10% by weight of the total weight of the formulation, (F) between 0 and 30% by weight of the total weight of the formulation of a chemical and/or physical stabilization agent (F), advantageously between 0 and 20% by weight of the total weight of the formulation, wherein when the formulation is in a form of a reverse emulsion or microemulsion and contains at least one hydrophilic solvent (E), the physical stabilization agent is present and is silicon dioxide. | 12-13-2012 |